SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the December 2025 quarter moved up 32.88% to Rs. 1247.20 millions as compared to Rs. 938.58 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2025 is Rs. -157.20 millions as compared to Net Loss of Rs. -404.00 millions of corresponding quarter ended December 2024 Operating profit Margin for the quarter ended December 2025 improved to 47.89% as compared to -38.45% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 1247.20 938.58 32.88 2895.23 2617.76 10.60 3813.04 4581.81 -16.78
Other Income 7.94 18.92 -58.03 23.75 47.81 -50.32 55.58 55.84 -0.47
PBIDT 47.89 -38.45 -224.55 -112.93 -669.37 -83.13 -606.36 -3.19 18908.15
Interest 71.77 99.22 -27.67 266.35 263.05 1.25 367.07 252.44 45.41
PBDT -44.82 -137.67 -67.44 -400.22 -932.42 -57.08 -973.43 -255.63 280.80
Depreciation 112.38 114.17 -1.57 332.05 321.83 3.18 437.74 363.13 20.55
PBT -157.20 -251.84 -37.58 -732.27 -1254.25 -41.62 -1411.17 -618.76 128.06
TAX 0.00 152.16 0.00 0.00 -67.15 0.00 -63.10 -148.89 -57.62
Deferred Tax 0.00 152.16 0.00 0.00 -67.15 0.00 -63.10 -148.89 -57.62
PAT -157.20 -404.00 -61.09 -732.27 -1187.10 -38.31 -1348.07 -469.87 186.90
Equity 222.82 196.11 13.62 222.82 196.11 13.62 196.11 196.09 0.01
PBIDTM(%) 3.84 -4.10 -193.73 -3.90 -25.57 -84.75 -15.90 -0.07 22748.13

Astec Lifesciences Share Price

715.65 8.65 (1.22%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
UPL 650.20
PI Industries 3097.65
Bayer CropScience 4643.90
Sharda Cropchem 1135.50
Sumitomo Chemical 498.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×